Compare Ascendis Pharma A/S (ASND) vs Global X Defense Tech ETF (SHLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Global X Defense Tech ETF — how do they compare? Ascendis Pharma A/S trades at $270.45 (market cap $17.74B), while Global X Defense Tech ETF trades at $61.09. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, Global X Defense Tech ETF nearer its low. Which is the better fit depends on your goals.
| ASND | SHLD | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | Sector/Thematic |
52-Week High | $277.18 | $78.02 |
52-Week Low | $163.32 | $58.20 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
SHLD, the Global X Defense Tech ETF, trades at $61.19, down 0.44% on the day, with technical indicators showing a bearish trend. The ETF provides diversified exposure to global defense technology companies, benefiting from rising military spending worldwide. Recent news highlights focus on defense sector growth, with articles discussing the UK's $20 billion military overhaul and ongoing geopolitical tensions driving demand.
The outlook for SHLD is supported by structural increases in global defense budgets, but faces risks from political shifts and valuation concerns. Analyst sentiment is mixed, with some seeing a rebound opportunity from current levels, while technical weakness suggests near-term caution. The ETF's performance will hinge on sustained government spending and sector earnings growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Global X Defense Tech ETF
SHLD tracks the Global X Defense Tech Index, targeting companies that lead the technological transformation of the defense sector. It focuses on pure-play innovators in cybersecurity, artificial intelligence, robotics, and advanced military systems, excluding traditional commercial aerospace to maintain a high level of thematic purity.
Read more on SHLD →
